Squamous NSCLC is associated with poorer prognosis than adenocarcinoma1,2a

squamous-nsclc
a1-year survival for advanced squamous NSCLC is 14.6% compared to 29.1% for advanced adenocarcinoma NSCLC.

Squamous NSCLC is associated with poorer prognosis than adenocarcinoma1,2a

squamous-nsclc

Squamous tumors are often centrally located3,4

Squamous cell carcinoma is often associated with a history of smoking3

Squamous tumors have been shown to grow at twice the pace of adenocarcinoma tumors2,5

a1-year survival for advanced squamous NSCLC is 14.6% compared to 29.1% for advanced adenocarcinoma NSCLC.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.